Withdrawal of HF therapy in recovered AF-mediated cardiomyopathy: clarifying trial designs

Key Points

• The aim is to clarify the impact of withdrawing HF therapy in patients who have recovered from AF-mediated cardiomyopathy.
• Randomized trial design
• Included patients with recovered AF-mediated cardiomyopathy
• Evaluated the effects of HF therapy withdrawal on heart function
• Significant improvement in heart function observed after withdrawal of HF therapy (p<0.05)
• Patients maintained recovery status without HF therapy for 12 months
• Reduced adverse events associated with continued HF therapy usage